Latanoprost/Timolol Stada (Latanoprost, Timolol)

• Latanoprost/Timolol is used in the management of glaucoma‑related conditions to reduce intra‑ocular pressure.
• Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage.
• Ocular hypertension: reduces pressure to lower the risk of progression to glaucoma.
• Combination therapy for ocular hypertension: provides additive pressure reduction when monotherapy is insufficient.

• Latanoprost increases uveoscleral outflow of aqueous humor by activating prostaglandin F receptors in the ciliary body, while Timolol blocks β‑adrenergic receptors in the ciliary epithelium, decreasing aqueous humor production. The dual action results in a net reduction of intra‑ocular pressure.

Latanoprost/Timolol may cause ocular and systemic adverse reactions.

Common Side Effects

• Eye irritation or burning sensation
• Blurred vision shortly after instillation
• Conjunctival hyperemia (redness)
• Increased eyelash growth
• Darkening of the iris color
• Foreign body sensation in the eye

Serious or Rare Side Effects

• Allergic eye reaction (e.g., swelling, rash)
• Severe eye pain or corneal ulceration
• Marked bradycardia or heart block
• Bronchospasm or worsening asthma
• Systemic beta‑blocker effects (e.g., hypotension)
• Acute angle‑closure glaucoma (rare).

• Before prescribing Latanoprost/Timolol, clinicians should consider several safety aspects.
• Assess baseline intra‑ocular pressure: ensure appropriate measurement before initiation.
• Screen for beta‑blocker contraindications: avoid in patients with severe asthma, COPD, or bradycardia.
• Monitor for ocular irritation: advise patients to report persistent redness or pain.
• Avoid use in patients with known hypersensitivity to prostaglandins or beta‑blockers.
• Store at room temperature: keep bottle tightly closed, protect from light and freezing.

Latanoprost/Timolol can interact with other systemic or ocular agents.

Major Interactions (Avoid)

• Non‑selective beta‑blockers (e.g., propranolol) – risk of additive bradycardia.
• Asthma or severe COPD medications – may exacerbate bronchospasm.
• Cardiac conduction drugs (e.g., digoxin) – increased risk of heart block.
• Other ocular beta‑blocker drops – excessive IOP lowering.
• Systemic antihypertensives – may potentiate hypotension.

Moderate Interactions (Monitor Closely)

• Carbonic anhydrase inhibitor eye drops – additive IOP reduction.
• Other prostaglandin analogs – risk of ocular hyperemia.
• Anticholinergic eye drops – possible reduced efficacy.
• Systemic MAO inhibitors – monitor for cardiovascular effects.
• Herbal supplements affecting blood pressure – observe for changes in IOP control.